scholarly journals Effects and moderators of psychosocial interventions on quality of life, and emotional and social function in patients with cancer: An individual patient data meta-analysis of 22 RCTs

2018 ◽  
Vol 27 (4) ◽  
pp. 1150-1161 ◽  
Author(s):  
J. Kalter ◽  
I.M. Verdonck-de Leeuw ◽  
M.G. Sweegers ◽  
N.K. Aaronson ◽  
P.B. Jacobsen ◽  
...  
2017 ◽  
Vol 52 ◽  
pp. 91-104 ◽  
Author(s):  
Laurien M. Buffart ◽  
Joeri Kalter ◽  
Maike G. Sweegers ◽  
Kerry S. Courneya ◽  
Robert U. Newton ◽  
...  

2009 ◽  
Vol 10 (9) ◽  
pp. 865-871 ◽  
Author(s):  
Chantal Quinten ◽  
Corneel Coens ◽  
Murielle Mauer ◽  
Sylvie Comte ◽  
Mirjam AG Sprangers ◽  
...  

2020 ◽  
Author(s):  
Miao Wan ◽  
Xianggui Luo ◽  
Louis.B NDZANA MVOGO ◽  
Juan Wang ◽  
Chen Chang ◽  
...  

Abstract Objective To assess the impact of informing diagnosis and disease status on the quality of life in patients with cancer Method We searched the follow databases, Pubmed, CENTRAL(Cochrane Central Register of Controlled Trials), PsycINFO, WEB OF SCIENCE, Embase, CBM (Chinese Biomedical Literature database), WANFANG database (Chinese Medicine Premier), and CNKI (China National Knowledge Infrastructure). And the terms used are as follows: neoplasm, cancer, tumour, tumor, carcinoma, disclosure, truth telling, breaking bad news, knowledge, knowing, awareness, quality of life, QOL. Pairs of reviewers independently screened documents and extracted the data. Meta-analysis was conducted by Revman 5.0 software. Results There were 11740 records retrieved from databases and 23 studies were included finally. Meta-analysis of informed and uniformed cancer patients revealed no differences in both the general quality of life and symptoms of fatigue, pain, dyspnea, insomnia, appetite loss and diarrhea (P>0.05). Additionally, no difference in physical function, role function, cognitive activity and emotional function between the above 2 groups(P>0.05) were found. On the vitality area, the patients who were totally informed about their diagnosis had higher vitality than the uniformed patients. However, patients aware about their illnesses seemed to get lower scores in social function. Between the partly informed of the diagnosis and uninformed cancer patients, there were no differences in general quality of life, function domains and disease-related symptoms (P>0.05). Conclusion Informing the cancer patients their diagnosis may not have a bad effect on their quality of life. PROSPERO registration number CRD42017060073.


2021 ◽  
Author(s):  
Maria Margareta Pertl ◽  
Perez ◽  
Sonya Collier ◽  
Emer Guinan ◽  
Garret Monahan ◽  
...  

Abstract Background: Depression is common among patients with cancer and is associated with lower treatment participation, lower satisfaction with care, poorer quality of life, greater symptom burden, and higher healthcare costs. Various types of interventions (e.g., pharmacological, psychotherapy) are used for the treatment of depression. However, evidence for these among patients with cancer is limited. Furthermore, the relative effectiveness and acceptability of different approaches is unknown because a direct comparison between all available treatments has not been carried out. We will address this by conducting a network meta-analysis (NMA) of interventions for depression among people with cancer using a hybrid overview of reviews and systematic review methodology. Methods: We will search for and extract data from systematic reviews of randomised controlled trials (RCTs) of depression interventions for patients with cancer from inception, before performing a supplemental search for more recent RCTs. We will include RCTs comparing pharmacological, psychotherapy, exercise, combination therapy, collaborative care, or complementary and alternative medicine interventions with pill placebo, no treatment, waitlist, treatment as usual, or minimal treatment control groups, or directly in head-to-head trials, among adults who have a current or previous diagnosis of cancer and elevated depressive symptoms (scores above a cut-off on validated scales or meeting diagnostic criteria). Our primary outcomes will be change in depressive symptoms (standardised mean difference) and intervention acceptability (% who withdrew). Our secondary outcomes will be 6-month change in depressive symptoms, health-related quality of life, adverse events and mortality. We will independently screen for eligibility, extract data, and assess risk of bias using the RoB2 tool. We will use frequentist random-effects multivariate NMA in Stata, Rankograms and surface under the cumulative ranking curves to synthesize evidence and obtain a ranking of intervention groups. We will explore heterogeneity and inconsistency using local and global measures and evaluate the credibility of results using the Confidence in NEtwork Meta-Analysis (CINeMA) framework.Discussion: Our findings will provide the best available evidence for managing depression among patients with cancer. Such information will help to inform clinical guidelines, evidence-based treatment decisions and future research by identifying gaps in the current literature. Systematic review registration: Submitted to PROSPERO (record number: 290145), awaiting registration


2003 ◽  
Vol 37 (1) ◽  
pp. 11-21 ◽  
Author(s):  
Pamela J. Atherton ◽  
Britta Jasperson ◽  
Andrea Nibbe ◽  
Kate A. Clement-Brown ◽  
Cristine Allmer ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document